TACE: Readmission Rates for Outpatients Versus Overnight Observation

Patients who were discharged the same day after undergoing transarterial chemoembolization (TACE) had similar 30-day readmission rates to patients who were observed, according to a study published in JVIR.

The researchers identified 193 patients with hepatocellular carcinoma (HCC) who underwent 216 TACE procedures that took place from July 2013 to June 2016. TACE treatment was conventional/lipiodol transarterial chemoembolization with 50 mg doxorubicin/10 mg mitomycin-c/particles or drug-eluting embolics transarterial chemoembolization with 50–75 mg doxorubicin/vial. Patients who tolerated oral intake and did not need intravenous analgesics were considered for discharge after 3 hours.

Results showed that the 179 observed patients had 30-day readmission rates that did not significantly differ from those of the 82 discharged patients. There was no relationship between readmission and type of agent selected. Additionally, patients aged less than 65 years did not have readmission rates that were different from patients aged 65 years or older. Patients with 1 tumor had rates similar to those of patients with more than one tumor, and segmental versus lobar embolization also did not predict readmission rates.

There were several baseline variables that were linked with higher risk of readmission though. These variables were Child-Pugh B/C, history of encephalopathy, and ascites.

—Lauren LeBano


Fritsche MR, Watchmaker JM, Lipnik AJ, et al. Outpatient transarterial chemoembolization of hepatocellular carcinoma: review of a same-day discharge strategy. J Vasc Interv Radiol. 2018 Feb 23. pii: S1051-0443(17)31038-2. doi: 10.1016/j.jvir.2017.11.018. [Epub ahead of print].